Key Insights

Highlights

Success Rate

71% trial completion

Published Results

16 trials with published results (5%)

Research Maturity

77 completed trials (26% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.9%

32 terminated out of 293 trials

Success Rate

70.6%

-15.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

21%

16 of 77 completed with results

Key Signals

16 with results71% success32 terminated

Data Visualizations

Phase Distribution

268Total
Not Applicable (33)
Early P 1 (3)
P 1 (212)
P 2 (20)

Trial Status

Recruiting89
Completed77
Unknown41
Terminated32
Active Not Recruiting31
Withdrawn11

Trial Success Rate

70.6%

Benchmark: 86.6%

Based on 77 completed trials

Clinical Trials (293)

Showing 20 of 20 trials
NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT07718581Phase 1RecruitingPrimary

HMPL-A830 in Solid Tumors

NCT07664397Phase 1Recruiting

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

NCT06625775Phase 1RecruitingPrimary

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT05868226Phase 1Recruiting

PRE-ISPY Phase I/II Oncology Platform Program

NCT06098651Phase 1CompletedPrimary

A Study of DCR-STAT3 in Adults With Solid Tumors

NCT04981119RecruitingPrimary

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT06788509Phase 1Enrolling By Invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06218914Phase 1Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06088004Phase 1RecruitingPrimary

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

NCT06915753Phase 1Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT04221204Phase 1CompletedPrimary

A Monotherapy in Subjects With Advanced Solid Tumors

NCT06714617Phase 1Terminated

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

NCT06398418Phase 1RecruitingPrimary

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

NCT02974738Phase 1Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

NCT04165772Phase 2Recruiting

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

NCT05230186CompletedPrimary

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT07225088Not ApplicableRecruiting

DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

NCT06292845Not ApplicableRecruitingPrimary

Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents

NCT04739696Not ApplicableActive Not Recruiting

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

Scroll to load more

Research Network

Activity Timeline